Sherwin-Williams Takes Valspar for $11.3 billion

US paint company Sherwin-Williams is to acquire rival firm Valspar for $11.3 billion in an all-cash deal.

Sherwin-Williams will pay $113 per share, which represents a premium of around 41% on Valspar’s volume weighted average price for the 30 days up to and including Mar. 18.

The transaction has been unanimously approved by both boards and is expected to close by the end of quarter one 2017, subject to the approval of Valspar shareholders and the usual closing conditions.

Describing Valspar as an excellent strategic fit, John Morikis, president and CEO of Sherwin-Williams, said: “The combination expands our brand portfolio and customer relationships in North America, significantly strengthens our Global Finishes business and extends our capabilities into new geographies and applications, including a scale platform to grow in Asia-Pacific and EMEA (Europe, Middle East and Africa).”

The combined company would have pro forma 2015 revenues of approximately $15.6 billion and adjusted EBITDA of $2.8 billion (including estimated annual synergies), with around 58,000 employees. The transaction is expected to immediately increase earnings, excluding one-time costs.

Estimated annual synergies of $280 million are expected to be realized within two years in the areas of sourcing, process and efficiency.

As both businesses are highly complementary, the companies believe that no or minimal divestments would be required to satisfy antitrust regulators. However, they said in the unlikely event that businesses totaling more than $650 million of Valspar’s 2015 revenue had to be sold, the transaction price would be adjusted to $105 per Valspar share.

Sherwin-Williams would have the right to terminate the deal if required divestments exceed $1.5 billion in 2015 revenues.

The transaction is to be financed through a combination of cash on hand, liquidity available under existing facilities and new debt.

Sherwin-Williams will remain headquartered in Cleveland; Valspar is based in Minneapolis.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.